Compare NINE & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NINE | LIXT |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 25.4M |
| IPO Year | 2018 | N/A |
| Metric | NINE | LIXT |
|---|---|---|
| Price | $0.33 | $3.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 98.1K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $571,171,000.00 | N/A |
| Revenue This Year | $4.56 | N/A |
| Revenue Next Year | $1.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.59 | N/A |
| 52 Week Low | $0.29 | $0.64 |
| 52 Week High | $1.78 | $6.26 |
| Indicator | NINE | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 40.41 |
| Support Level | $0.29 | $4.01 |
| Resistance Level | $0.51 | $4.31 |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 19.37 | 38.95 |
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.